切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™红细胞去除试剂

红细胞的免疫磁珠去除
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #18170_C

红细胞的免疫磁珠去除

产品优势

  • 99.9%的红细胞去除率，无需密度梯度离心、沉降或裂解
  • 快捷、操作简单，且无需分离柱
  • 分选得到的细胞无标记

产品组分包括

  • EasySep™ RBC去除试剂（产品号 #18170）
  • EasySep™红细胞去除试剂，10 mL
  • 用于RoboSep™的EasySep™ RBC去除试剂（产品号 #18170RF）
  • 用于RoboSep™的EasySep™红细胞去除试剂，4 x 2.5 mL
  • RoboSep™ 缓冲液（产品号 #20104）x 2
  • RoboSep™ 过滤吸头（产品号 #20125）x 2
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

EasySep™红细胞去除试剂专为从人新鲜外周血、脐带血、骨髓或白细胞单采术样本中通过免疫磁珠去除红细胞(RBCs)而设计。红细胞被被识别糖蛋白A的抗体复合物和磁珠标记，通过EasySep™磁极进行无柱分选，被磁珠标记的红细胞留在管中，而未被标记的目的细胞则被倾倒或吸取至新的管中即可。

该产品可替代EasySep™人糖蛋白A去除试剂盒 (产品号 #18352) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

该产品可替代EasySep™人糖蛋白A去除试剂盒 (产品号 #18352) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

该产品可替代EasySep™人糖蛋白A去除试剂盒 (产品号 #18352) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

该产品可替代EasySep™人糖蛋白A去除试剂盒 (产品号 #18352) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • Easy 50 EasySep™ Magnet (Catalog #18002) • EasyPlate™ EasySep™ Magnet (Catalog #18102)
 
种属
人
 
样本来源
Whole Blood
 
筛选方法
Negative
 
品牌
EasySep，RoboSep
 
研究领域
嵌合体，药物发现和毒理检测，HLA，免疫
 

查看更多 显示更少

实验数据

Figure 1. EasySep™ RBC Depletion Reagent Provides Superior RBC Depletion Compared to Ammonium Chloride Lysis

Different types of RBC-containing samples from normal healthy donors were processed to remove RBCs by using either ammonium chloride (NH4Cl) lysis or immunomagnetic depletion with EasySep™ RBC Depletion Reagent. After RBC removal, samples were stained with fluorochrome-conjugated anti-CD45 and anti-Glycophorin A antibodies and analyzed by flow cytometry. Residual RBCs were identified as Glycophorin A+/CD45− events. (A) The percentages of residual RBCs in various samples following use of EasySep™ RBC Depletion Reagent was significantly lower compared to samples treated with ammonium chloride (mean ± SD; n = 31). (B) Both, RBC lysis with ammonium chloride and RBC removal using EasySep™ RBC Depletion Reagent resulted in an equivalent total number of white blood cells recovered from whole blood samples (mean ± SD; n = 37).

Figure 2. Typical RBC Removal Using EasySep™ RBC Depletion Reagent With Human Whole Blood Samples

Starting with human whole blood from normal healthy donors, the percentage of residual RBCs (Glycophorin A+/CD45-) following use of EasySep™ RBC Depletion Reagent is typically 2 ± 3 (mean ± SD; n = 31). In the above example, the residual RBC content is 0.05%.

Figure 3. Typical RBC Removal Using EasySep™ RBC Depletion Reagent With Human Bone Marrow Samples

Starting with human bone marrow, the percentage of residual RBCs (Glycophorin A+/CD45-) following use of EasySep™ RBC Depletion Reagent is typically 0.39 ± 0.34 (mean ± SD; n = 5). In the above example, the residual RBC content is 0.57%.

Figure 4. Typical RBC Removal Using EasySep™ RBC Depletion Reagent With Buffy Coat Samples

Starting with buffy coat, the percentage of residual RBCs (Glycophorin A+/CD45-) following use of EasySep™ RBC Depletion Reagent is typically 0.12 ± 0.08 (mean ± SD; n = 6). In the above example, the residual RBC content is 0.26%.

Figure 5. Typical RBC Removal Using EasySep™ RBC Depletion Reagent With Cord Blood Samples

Starting with cord blood, the percentage of residual RBCs (Glycophorin A+/CD45-) following use of EasySep™ RBC Depletion Reagent is typically 1.7 ± 2.2 (mean ± SD; n = 16). In the above example, the residual RBC content is 0.08%.

Figure 6. Typical RBC Removal Using EasySep™ RBC Depletion Reagent With Leukapheresis Samples

Starting with leukapheresis samples, the percentage of residual RBCs (Glycophorin A+/CD45-) following use of EasySep™ RBC Depletion Reagent is typically 0.5 ± 0.8 (mean ± SD; n = 15). In the above example, the residual RBC content is 0.6%.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet - Bone Marrow
Product Name
EasySep™ RBC Depletion Reagent - 10mL
Catalog #
18170
Lot #
All
Language
English
Document Type
Product Information Sheet - Whole Blood
Product Name
EasySep™ RBC Depletion Reagent - 10mL
Catalog #
18170
Lot #
All
Language
English
Document Type
Product Information Sheet - Cord Blood
Product Name
EasySep™ RBC Depletion Reagent - 10mL
Catalog #
18170
Lot #
All
Language
English
Document Type
Product Information Sheet - Whole Blood
Product Name
EasySep™ RBC Depletion Reagent - 10mL
Catalog #
18170
Lot #
All
Language
English
Document Type
Product Information Sheet - Leukapheresis
Product Name
EasySep™ RBC Depletion Reagent - 10mL
Catalog #
18170
Lot #
All
Language
English
Document Type
Product Information Sheet - Buffy Coat
Product Name
EasySep™ RBC Depletion Reagent - 10mL
Catalog #
18170
Lot #
All
Language
English
Document Type
Product Information Sheet - Bone Marrow
Product Name
EasySep™ RBC Depletion Reagent for RoboSep
Catalog #
18170RF
Lot #
All
Language
English
Document Type
Product Information Sheet - Cord Blood
Product Name
EasySep™ RBC Depletion Reagent for RoboSep
Catalog #
18170RF
Lot #
All
Language
English
Document Type
Product Information Sheet - Whole Blood
Product Name
EasySep™ RBC Depletion Reagent for RoboSep
Catalog #
18170RF
Lot #
All
Language
English
Document Type
Product Information Sheet - Whole Blood
Product Name
EasySep™ RBC Depletion Reagent for RoboSep
Catalog #
18170RF
Lot #
All
Language
English
Document Type
Product Information Sheet - Leukapheresis
Product Name
EasySep™ RBC Depletion Reagent for RoboSep
Catalog #
18170RF
Lot #
All
Language
English
Document Type
Product Information Sheet - Buffy Coat
Product Name
EasySep™ RBC Depletion Reagent for RoboSep
Catalog #
18170RF
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
EasySep™ RBC Depletion Reagent - 10mL
Catalog #
18170
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ RBC Depletion Reagent for RoboSep
Catalog #
18170RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ RBC Depletion Reagent for RoboSep
Catalog #
18170RF
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (15)

Cell Enrichment Prior to Cell Sorting
Brochure
Cell Enrichment Prior to Cell Sorting
EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Isolate Human Immune Cells
Brochure
Isolate Human Immune Cells
EasySep™ RBC Depletion Reagent
Brochure
EasySep™ RBC Depletion Reagent
The Immune Response to HIV Poster
Wallchart
The Immune Response to HIV Poster
Production of Chimeric Antigen Receptor T Cells
Wallchart
Production of Chimeric Antigen Receptor T Cells
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Antigen Processing and Presentation
Wallchart
Antigen Processing and Presentation
How to Isolate Cells in 96-Well Plates Using the EasyPlate™ Cell Separation Magnet
2:34
Video
How to Isolate Cells in 96-Well Plates Using the EasyPlate™ Cell Separation Magnet
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep™)
1:37
Video
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep...
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
Centrifugation and RBC Lysis-Free Preparation of Blood Samples in Under 30 Minutes
Scientific Poster
Centrifugation and RBC Lysis-Free Preparation of Blood Samples in Under 30 Minutes
Human Immune Cell Isolation Course
On-Demand Training
Human Immune Cell Isolation Course

文献 (3)

Single-cell analysis of menstrual endometrial tissues defines phenotypes associated with endometriosis. A. J. Shih et al. BMC medicine 2022 sep

Abstract

BACKGROUND Endometriosis is a common, complex disorder which is underrecognized and subject to prolonged delays in diagnosis. It is accompanied by significant changes in the eutopic endometrial lining. METHODS We have undertaken the first single-cell RNA-sequencing (scRNA-Seq) comparison of endometrial tissues in freshly collected menstrual effluent (ME) from 33 subjects, including confirmed endometriosis patients (cases) and controls as well as symptomatic subjects (who have chronic symptoms suggestive of endometriosis but have not been diagnosed). RESULTS We identify a unique subcluster of proliferating uterine natural killer (uNK) cells in ME-tissues from controls that is almost absent from endometriosis cases, along with a striking reduction of total uNK cells in the ME of cases (p??<??10-16). In addition, an IGFBP1+ decidualized subset of endometrial stromal cells are abundant in the shed endometrium of controls when compared to cases (p??<??10-16) confirming findings of compromised decidualization of cultured stromal cells from cases. By contrast, endometrial stromal cells from cases are enriched in cells expressing pro-inflammatory and senescent phenotypes. An enrichment of B cells in the cases (p??=??5.8???—??10-6) raises the possibility that some may have chronic endometritis, a disorder which predisposes to endometriosis. CONCLUSIONS We propose that characterization of endometrial tissues in ME will provide an effective screening tool for identifying endometriosis in patients with chronic symptoms suggestive of this disorder. This constitutes a major advance, since delayed diagnosis for many years is a major clinical problem in the evaluation of these patients. Comprehensive analysis of ME is expected to lead to new diagnostic and therapeutic approaches to endometriosis and other associated reproductive disorders such as female infertility.
View publication
Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestation. J. D. Matute et al. Pediatric research 2022 apr

Abstract

BACKGROUND During the COVID-19 pandemic, thousands of pregnant women have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The implications of maternal SARS-CoV-2 infection on fetal and childhood well-being need to be characterized. We aimed to characterize the fetal immune response to maternal SARS-CoV-2 infection. METHODS We performed single-cell RNA-sequencing and T cell receptor sequencing on cord blood mononuclear cells (CBMCs) from newborns of mothers infected with SARS-CoV-2 in the third trimester (cases) or without SARS-CoV-2 infection (controls). RESULTS We identified widespread gene expression changes in CBMCs from cases, including upregulation of interferon-stimulated genes and major histocompatibility complex genes in CD14+ monocytes, transcriptional changes suggestive of activation of plasmacytoid dendritic cells, and activation and exhaustion of natural killer cells. Lastly, we observed fetal T cell clonal expansion in cases compared to controls. CONCLUSIONS As none of the infants were infected with SARS-CoV-2, our results suggest that maternal SARS-CoV-2 infection might modulate the fetal immune system in the absence of vertical transmission. IMPACT The implications of maternal SARS-CoV-2 infection in the absence of vertical transmission on fetal and childhood well-being are poorly understood. Maternal SARS-CoV-2 infection might modulate the fetal immune system in the absence of vertical transmission. This study raises important questions about the untoward effects of maternal SARS-CoV-2 on the fetus, even in the absence of vertical transmission.
View publication
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. G. Leclercq et al. Oncoimmunology 2022

Abstract

T cell engagers represent a novel promising class of cancer-immunotherapies redirecting T cells to tumor cells and have some promising outcomes in the clinic. These molecules can be associated with a mode-of-action related risk of cytokine release syndrome (CRS) in patients. CRS is characterized by the rapid release of pro-inflammatory cytokines such as TNF-$\alpha$, IFN-$\gamma$, IL-6 and IL-1$\beta$ and immune cell activation eliciting clinical symptoms of fever, hypoxia and hypotension. In this work, we investigated the biological mechanisms triggering and amplifying cytokine release after treatment with T cell bispecific antibodies (TCBs) employing an in vitro co-culture assay of human PBMCs or total leukocytes (PBMCs + neutrophils) and corresponding target antigen-expressing cells with four different TCBs. We identified T cells as the triggers of the TCB-mediated cytokine cascade and monocytes and neutrophils as downstream amplifier cells. Furthermore, we assessed the chronology of events by neutralization of T-cell derived cytokines. For the first time, we demonstrate the contribution of neutrophils to TCB-mediated cytokine release and confirm these findings by single-cell RNA sequencing of human whole blood incubated with a B-cell depleting TCB. This work could contribute to the construction of mechanistic models of cytokine release and definition of more specific molecular and cellular biomarkers of CRS in the context of treatment with T-cell engagers. In addition, it provides insight for the elaboration of prophylactic mitigation strategies that can reduce the occurrence of CRS and increase the therapeutic index of TCBs.
View publication
View All Publications

更多信息

更多信息
种属 Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • Easy 50 EasySep™ Magnet (Catalog #18002) • EasyPlate™ EasySep™ Magnet (Catalog #18102)
样本来源 Whole Blood
Selection Method Negative
标记抗体
  1. 抗人CD235（血型糖蛋白A/B）抗体，克隆HIR2
    抗人CD235（血型糖蛋白A/B）抗体，克隆HIR2

    小鼠单克隆IgG2b抗体，抗人糖蛋白A/B

质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.